MedMira Increases Global Sales Force to Capitalize on Product Approvals

Opportunities in Europe, China, and Developing Nations Being Pursued

Jun 29, 2006, 01:00 ET from MedMira Inc.

    HALIFAX, June 29 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
 (TSX Venture: MIR, NASDAQ:   MMIRF) a global market leader in premium rapid
 diagnostic solutions, announced today that it has expanded its global sales
 team in order to capitalize on market penetration opportunities from
 recently completed key regulatory approvals.
     The expansion includes two new regional account managers dedicated to
 the Europe/Middle East and Latin America markets. Jaime Carreno and Pierre
 Sevigny together bring over 25 years of experience selling medical and
 technical products in these markets to the MedMira team.
     "We are very pleased to have these individuals on board and dedicated
 to leveraging sales opportunities in these important regions," said Hermes
 Chan, President & COO, MedMira Inc. "Ramping up our sales capabilities will
 enable us to better meet the needs of distributors and customers in
 critical global markets, like Latin America and Europe."
     After receiving CE Mark in early 2006 for its MiraCare(TM) Rapid HIV
 Antibody Test (MiraCare HIV), MedMira strategically selected countries in
 which to register with the Competent Authority, governing bodies within
 each member country regulating the sale of medical devices. MedMira's
 Regulatory Team has completed 13 registrations, the final step in the
 regulatory process, and will continue to pursue registrations in strategic
 country markets where sales opportunities exist.
     In Asia, MedMira has engaged MediServe Inc., a leading consulting group
 to head-up the company's sales and marketing activities in that region.
 MediServe is a partnership of project managers, medical doctors and
 healthcare practitioners, each with over 10 years of marketing and
 healthcare experience in Asia. The partners have a strong track record of
 serving international players such as Merck and their strengths include
 sales and distribution channel management and outsourcing business
 projects. MediServe was on-site at MedMira corporate headquarters in
 Halifax early this month to receive in-depth product training and finalize
 plans to launch MedMira's recently approved whole blood rapid HIV test in
 China. In April 2006, MedMira received a fast- tracked approval for the
 first and only whole blood rapid HIV test available in China. This approval
 enables MediServe to quickly capitalize on a key competitive advantage for
 MedMira in the China market.
     "With this latest whole blood approval and our new on-the-ground sales
 and marketing team in place, the timing is right to create a unique niche
 market for MedMira in China," said Chan. "We will also turn our attention
 to increasing MedMira's presence in developing nations, becoming part of
 their large scale testing programs."
     Richard Van Maanen, a biotechnology consultant and a former sales and
 marketing executive with another leading diagnostics manufacturer has been
 engaged by MedMira. Mr. Van Maanen will focus on increasing MedMira's
 profile with the international agencies and non-government organizations
 (NGOs) that provide testing solutions and programs to Africa and other
 developing nations. He will also identify qualified distributors and
 initiate local product registrations for MedMira in the Sub-Saharan region.
     MedMira's new sales & marketing team members will be travelling to
 various countries in their respective territories in the coming months,
 seeking new distributors in untapped markets, managing distributor
 relationships and capitalizing on sales opportunities for MedMira products.
 Additionally, MedMira will be taking part in the American Association for
 Clinical Chemistry's Clinical Lab Expo, July 25-27 in Chicago and the XVI
 International AIDS Conference (AIDS 2006) in Toronto, August 13-18. AIDS
 2006 is a biennial conference that draws members of the international
 scientific, political, and business communities together to discuss and
 develop strategies to fight HIV/AIDS.
     On the regulatory front, MedMira continues preparations to enter the US
 market with an over-the-counter (OTC) rapid HIV test. MedMira has submitted
 a proposed solution to the FDA and is ready to begin the market entry and
 regulatory process once the proposal is reviewed. MedMira's proposed US OTC
 solution is built on the company's solid experience in the Hong Kong OTC
 market, where it successfully launched its MiraCare HIV test in 2005.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro
 flow- through rapid diagnostic tests. MedMira's tests provide reliable,
 rapid diagnosis in just 3 minutes for the detection of human antibodies in
 human serum, plasma or whole blood for diseases such as HIV and hepatitis
 C. The United States FDA, the SFDA in the People's Republic of China and
 European Union have approved MedMira's Reveal(R) G2, MiraWell(R) and
 MiraCare(TM) rapid HIV tests, respectively.
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently
 used in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     MiraCare(TM) is sold through MedMira's distributor network to
 pharmacies, hospitals and laboratories in the European Union. It is also
 available over- the-counter (OTC) in pharmacies throughout Hong Kong and
 Macao Special Administrative Regions, in the People's Republic of China.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office and
 joint venture manufacturing facility in Guilin, China.
     This news release contains forward-looking statements, which involve
 risk and uncertainties and reflect the company's current expectation
 regarding future events. Actual events could materially differ from those
 projected herein and depend on a number of factors including, but not
 limited to, changing market conditions, successful and timely completion of
 clinical studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.